274 related articles for article (PubMed ID: 9933821)
21. New cut-off values for screening of trisomy 21, 18 and open neural tube defects (ONTD) during the second trimester in pregnant women with advanced maternal age.
Chen Y; Wang X; Li L; Lu S; Zhang Z
BMC Pregnancy Childbirth; 2020 Dec; 20(1):776. PubMed ID: 33317474
[TBL] [Abstract][Full Text] [Related]
22. Prenatal screening for fetal aneuploidy in singleton pregnancies.
Chitayat D; Langlois S; Douglas Wilson R; ;
J Obstet Gynaecol Can; 2011 Jul; 33(7):736-750. PubMed ID: 21749752
[TBL] [Abstract][Full Text] [Related]
23. Triploidy identified through second-trimester serum screening.
Huang T; Alberman E; Wald N; Summers AM
Prenat Diagn; 2005 Mar; 25(3):229-33. PubMed ID: 15791661
[TBL] [Abstract][Full Text] [Related]
24. Assay precision of serum alpha fetoprotein in antenatal screening for neural tube defects and Down's syndrome.
Wald NJ; Hackshaw AK; George LM
J Med Screen; 2000; 7(2):74-7. PubMed ID: 11002446
[TBL] [Abstract][Full Text] [Related]
25. Prenatal maternal dried blood screening with alpha-fetoprotein and free beta-human chorionic gonadotropin for open neural tube defect and Down syndrome.
Macri JN; Anderson RW; Krantz DA; Larsen JW; Buchanan PD
Am J Obstet Gynecol; 1996 Feb; 174(2):566-72. PubMed ID: 8623786
[TBL] [Abstract][Full Text] [Related]
26. The effect of temporal variation in biochemical markers of trisomy 21 across the first and second trimesters of pregnancy on the estimation of individual patient-specific risks and detection rates for Down's syndrome.
Spencer K; Crossley JA; Aitken DA; Nix AB; Dunstan FD; Williams K
Ann Clin Biochem; 2003 May; 40(Pt 3):219-31. PubMed ID: 12803832
[TBL] [Abstract][Full Text] [Related]
27. Screening for fetal Down's syndrome in pregnancy by measuring maternal serum alpha-fetoprotein levels.
DiMaio MS; Baumgarten A; Greenstein RM; Saal HM; Mahoney MJ
N Engl J Med; 1987 Aug; 317(6):342-6. PubMed ID: 2439909
[TBL] [Abstract][Full Text] [Related]
28. Screening of maternal serum for fetal Down's syndrome in the first trimester.
Haddow JE; Palomaki GE; Knight GJ; Williams J; Miller WA; Johnson A
N Engl J Med; 1998 Apr; 338(14):955-61. PubMed ID: 9521983
[TBL] [Abstract][Full Text] [Related]
29. Prenatal biochemical screening for Down's syndrome and neural tube defects.
Wald NJ; Kennard A
Curr Opin Obstet Gynecol; 1992 Apr; 4(2):302-7. PubMed ID: 1373963
[TBL] [Abstract][Full Text] [Related]
30. First-trimester or second-trimester screening, or both, for Down's syndrome.
Malone FD; Canick JA; Ball RH; Nyberg DA; Comstock CH; Bukowski R; Berkowitz RL; Gross SJ; Dugoff L; Craigo SD; Timor-Tritsch IE; Carr SR; Wolfe HM; Dukes K; Bianchi DW; Rudnicka AR; Hackshaw AK; Lambert-Messerlian G; Wald NJ; D'Alton ME;
N Engl J Med; 2005 Nov; 353(19):2001-11. PubMed ID: 16282175
[TBL] [Abstract][Full Text] [Related]
31. Experience on triple markers serum screening for Down's syndrome fetus in Hat Yai, Regional Hospital.
Lamlertkittikul S; Chandeying V
J Med Assoc Thai; 2007 Oct; 90(10):1970-6. PubMed ID: 18041410
[TBL] [Abstract][Full Text] [Related]
32. Prospective study of prenatal screening for Down's syndrome with free beta human chorionic gonadotrophin.
Spencer K; Carpenter P
BMJ; 1993 Sep; 307(6907):764-9. PubMed ID: 7693095
[TBL] [Abstract][Full Text] [Related]
33. Effectiveness of combining maternal serum alpha-fetoprotein and hCG in a second-trimester screening program for Down syndrome.
Mooney RA; Peterson CJ; French CA; Saller DN; Arvan DA
Obstet Gynecol; 1994 Aug; 84(2):298-303. PubMed ID: 7518896
[TBL] [Abstract][Full Text] [Related]
34. Second-trimester maternal serum alpha-fetoprotein and human chorionic gonadotrophin screening for Down's syndrome in Hong Kong.
Lam YH; Ghosh A; Tang MH; Tang LC; Lee CP; Sin SY; Ho PK
Prenat Diagn; 1998 Jun; 18(6):585-89. PubMed ID: 9664604
[TBL] [Abstract][Full Text] [Related]
35. Down's syndrome: current screening techniques.
White RS
South Med J; 1989 Dec; 82(12):1483-6. PubMed ID: 2480649
[TBL] [Abstract][Full Text] [Related]
36. Antenatal maternal serum screening for Down's syndrome: results of a demonstration project.
Wald NJ; Kennard A; Densem JW; Cuckle HS; Chard T; Butler L
BMJ; 1992 Aug; 305(6850):391-4. PubMed ID: 1382768
[TBL] [Abstract][Full Text] [Related]
37. Implementation of an antenatal serum screening programme for Down's syndrome in two districts (Brighton and Eastbourne). The Brighton and Eastbourne Down's Syndrome Screening Group.
Piggott M; Wilkinson P; Bennett J
J Med Screen; 1994 Jan; 1(1):45-9. PubMed ID: 8790485
[TBL] [Abstract][Full Text] [Related]
38. Antenatal screening for Down's syndrome.
Wald NJ; Kennard A; Hackshaw A; McGuire A
J Med Screen; 1997; 4(4):181-246. PubMed ID: 9494915
[TBL] [Abstract][Full Text] [Related]
39. Maternal serum screening for Down's syndrome: the effect of routine ultrasound scan determination of gestational age and adjustment for maternal weight.
Wald NJ; Cuckle HS; Densem JW; Kennard A; Smith D
Br J Obstet Gynaecol; 1992 Feb; 99(2):144-9. PubMed ID: 1372820
[TBL] [Abstract][Full Text] [Related]
40. Impact of a regional screening programme using maternal serum alpha fetoprotein (AFP) and human chorionic gonadotrophin (hCG) on the birth incidence of Down's syndrome in the west of Scotland.
Crossley JA; Aitken DA; Berry E; Connor JM
J Med Screen; 1994 Jul; 1(3):180-3. PubMed ID: 8790513
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
